Gemini Therapeutics, Inc. /DE

Gemini Therapeutics, Inc. /DE insiders are currently net buyers of GMTX stock, showing bullish sentiment over the past 90 days. Executives have purchased $1.5M while selling $47.0K, resulting in a positive net flow of $1.5M. This buying activity represents 97% of total transaction volume.

Gemini Therapeutics, Inc. /DE has 5 active insiders who have filed SEC Form 4 transactions in the past 90 days. Capital Opportunity Management V, Llc Foresite (Executive) leads with 2 transactions totaling $15.0M. James B. Tananbaum (Executive) follows with 2 transactions worth $15.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Gemini Therapeutics, Inc. /DE's current score of 97/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $1.5M in purchases versus $47.0K in sales.

The most recent insider transaction occurred on Oct 26, 2022, when Michael Leonard Braden (Executive) disposed of 22,500 shares at $2.09 per share for $47.0K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, GMTX insider trading sentiment is currently bullish with an Alignment Score of 97/100. The net insider flow of $1.5M reflects accumulation, with 97% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Gemini Therapeutics, Inc. /DE. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At GMTX, we track all Form 4 filings—currently showing 12 transactions from 5 insiders over 90 days.

A 10b5-1 plan allows Gemini Therapeutics, Inc. /DE executives to pre-schedule stock sales when they don't possess material non-public information. At GMTX, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at GMTX appears discretionary, making insider signals more meaningful.

You can monitor Gemini Therapeutics, Inc. /DE (GMTX) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 5 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Gemini Therapeutics, Inc. /DE's current score of 97/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $1.5M in purchases versus $47.0K in sales over 90 days, resulting in a net flow of $1.5M.

SEC Form 4 filings are mandatory reports that Gemini Therapeutics, Inc. /DE insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At GMTX, the most common type is "P" with 6 occurrences. The most recent Form 4 was filed on Oct 26, 2022 by Michael Leonard Braden.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Gemini Therapeutics, Inc. /DE, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at GMTX represents discretionary decisions with more informational value.